Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Update

Immix Biopharma, Inc. (NASDAQ:IMMX) saw a large drop in short interest in the month of July. As of July 31st, there was short interest totalling 578,200 shares, a drop of 7.5% from the July 15th total of 625,300 shares. Currently, 3.8% of the shares of the company are short sold. Based on an average daily volume of 160,900 shares, the short-interest ratio is presently 3.6 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Immix Biopharma in a report on Monday.

Institutional Investors Weigh In On Immix Biopharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Invst LLC acquired a new stake in Immix Biopharma during the 2nd quarter worth $57,000. Tocqueville Asset Management L.P. raised its position in shares of Immix Biopharma by 89.0% in the first quarter. Tocqueville Asset Management L.P. now owns 37,800 shares of the company’s stock valued at $116,000 after buying an additional 17,800 shares during the last quarter. Tritonpoint Wealth LLC purchased a new position in shares of Immix Biopharma in the first quarter worth about $75,000. Jump Financial LLC acquired a new position in Immix Biopharma during the fourth quarter worth about $128,000. Finally, Private Advisor Group LLC acquired a new position in Immix Biopharma during the fourth quarter worth about $690,000. Hedge funds and other institutional investors own 11.26% of the company’s stock.

Immix Biopharma Trading Up 0.5 %

Immix Biopharma stock opened at $1.90 on Monday. The firm has a market cap of $50.19 million, a PE ratio of -2.04 and a beta of 0.17. Immix Biopharma has a 12 month low of $1.55 and a 12 month high of $7.75. The stock’s 50 day simple moving average is $2.09 and its two-hundred day simple moving average is $2.49.

Immix Biopharma (NASDAQ:IMMX) last posted its earnings results on Monday, August 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.06. On average, equities research analysts forecast that Immix Biopharma will post -0.88 EPS for the current year.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.